Instructions for Longidaza (Bovhyaluronidase azoximer) suppositories, vaginal and rectal
English product name
Longidaza
Form of release
Supp. vaginal and rectal 3000 IU: 10 pcs.
Description
Suppositories vaginal and rectal torpedo-shaped, light yellow, with a weak specific smell of cocoa butter, marbling of staining is allowed.
1 supp.
bovgialuronidase azoximer (Longidaza®) 3000 IU
Excipients: cocoa butter - until a suppository weighing 1.3 g.
ATC codes
V03AX Other Medicines
Clinical and pharmacological groups / Group affiliation
Enzyme preparation
Active ingredient
bovialuronidase azoximer
Pharmaco-therapeutic group
Enzyme agent
Storage conditions
The drug should be stored in a dry, protected from light, out of reach of children at a temperature of 2 ° to 15 ° C.
Shelf life
Shelf life – 2 years. Do not use after expiration date indicated on the package.
Testimony Longidaza:
Adults and adolescents over 12 years of age in the form of monotherapy and as part of the complex therapy of diseases accompanied by connective tissue hyperplasia (incl. against the background of the inflammatory process).
In urology:
- chronic prostatitis;
- interstitial cystitis;
- strictures of the urethra and ureters;
- Peyronie's disease;
- the initial stage of benign prostatic hyperplasia;
- prevention of scarring and strictures after surgical interventions on the urethra, bladder, ureters.
- In gynecology:
- prevention and treatment of adhesions in the pelvis in chronic inflammatory diseases of the internal genital organs;
- prevention and treatment of adhesions in the pelvis after gynecological manipulations (including artificial abortions,
- previous surgical interventions on the pelvic organs);
- intrauterine synechia;
- tubal-peritoneal infertility;
- chronic endomyometriitis.
- In dermatovenereology:
limited scleroderma;
prevention of fibrous complications of sexually transmitted infections.
In surgery:
prevention and treatment of adhesions after surgical interventions on the abdominal organs;
long-term non-healing wounds.
In pulmonology and phthisiology:
pneumofibrosis;
siderosis;
tuberculosis (cavernous-fibrous, infiltrative, tuberculema);
interstitial pneumonia;
fibrosing alveolitis;
pleurisy.
To increase the bioavailability of antibiotic therapy in urology, gynecology, dermatovenereology, surgery and pulmonology.
Method of administration, course and dosage:
Longidase® suppositories 3000 IU is recommended for rectal or intravaginal use once / day at night
Adults intravaginally: one suppository once a day at night; Suppositories are inserted into the vagina in the supine position.
Adolescents aged twelve to eight years suppositories are administered only rectally.
Adults and adolescents over 12 years of age rectally: one suppository once a day after cleansing the intestines.
The treatment regimen is adjusted depending on the severity, stage and duration of the disease. You can prescribe the drug every other day or with breaks of two to three days.
In urology
one suppository every other day - ten injections, then after two - three days - ten injections. General course of twenty introductions.
In gynecology
Rectally or intravaginally, one suppository after two days - ten injections, then, if necessary, maintenance therapy is prescribed.
In dermatovenereology
one suppository in one to two days, ten to five injections.
In surgery
one suppository after two to three days, ten injections.
In pulmonology and phthisiology
one suppository after two to four days – ten to twenty studies.
If necessary, a second course of Longidase is recommended® not earlier than three months or long-term maintenance therapy - one suppository once every five to seven days for three to four months.
Use in children
Contraindicated use of the drug in children under 12 years of age (the results of clinical studies are absent).
- Nosology Longidaza (ICD codes)
- A15
- Tuberculosis of the respiratory system, confirmed bacteriologically and histologically
- J63.4
- Siderosis
- J84.1
- Other interstitial pulmonary diseases with mention of fibrosis
- J84.9
- Interstitial pulmonary disease unspecified
- K66.0
- Abdominal adhesions
- L94.0
- Localized scleroderma [morphea]
- N30
- Cystitis
- N35
- Urethral stricture
- N40
- Prostatic hyperplasia
- N41
- Inflammatory diseases of the prostate gland
- N48
- Other penile diseases
- N71
- Inflammatory disease of the uterus, except for the cervix (incl. endometritis, myometritis, metritis, pyometra, uterine abscess)
- N85.6
- Intrauterine synechia
- N97
- Female infertility
- N99.4
- Postoperative adhesions in the pelvis
- R09.1
- Pleurisy
- T14.1
- Open wound of unspecified area of the body
Drugs Longidaza:
Longidaza has hyaluronidase (enzymatic) activity of prolonged action, chelating, antioxidant, immunomodulatory and moderately pronounced anti-inflammatory effect.
The prolonged action is achieved by covalent binding of the enzyme to a physiologically active polymer carrier (azoximer). Longidaza® exhibits antifibrouse properties, weakens the course of the acute phase of inflammation, regulates (increases or decreases, depending on the initial level) the synthesis of inflammatory mediators (interleukin-1 and TNFα), increases the humoral immune response and the body's resistance to infection.
The pronounced antifibrose properties of the drug Longidase® are provided by the conjugation of hyaluronidase with the carrier, which significantly increases the resistance of the enzyme to denaturing effects and the action of inhibitors: the enzymatic activity of the drug Longidaza® persists when heated to 37 ° C for twenty days, while the native hyaluronidase under the same conditions loses its activity during the day.
